ECSP024393A - SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH - Google Patents

SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH

Info

Publication number
ECSP024393A
ECSP024393A EC2002004393A ECSP024393A ECSP024393A EC SP024393 A ECSP024393 A EC SP024393A EC 2002004393 A EC2002004393 A EC 2002004393A EC SP024393 A ECSP024393 A EC SP024393A EC SP024393 A ECSP024393 A EC SP024393A
Authority
EC
Ecuador
Prior art keywords
treatment
compounds
formula
cellular growth
normal cellular
Prior art date
Application number
EC2002004393A
Other languages
Spanish (es)
Inventor
John Charles Kath
Joel Morris
Samit BHATTACHARYA
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP024393A publication Critical patent/ECSP024393A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula I: Y a sales solvatos o profármacos farmacéuticamente aceptable de los mismos, en los cuales R1, R3, R4, R5, R11, m y p son tales como se han definido en la presente memoria. La invención se refiere también a métodos para tratar el crecimiento celular anormal en animales mamíferos administrando los compuestos de fórmula I, y a composiciones farmacéuticas para tratar los trastornos, que contienen los compuestos de la fórmula I. La invención se refiere también a métodos para preparar los compuestos de fórmula I.The invention relates to compounds of formula I: And to pharmaceutically acceptable solvate salts or prodrugs thereof, in which R1, R3, R4, R5, R11, m and p are as defined herein. The invention also relates to methods for treating abnormal cell growth in mammalian animals by administering the compounds of formula I, and pharmaceutical compositions for treating disorders, which contain the compounds of formula I. The invention also relates to methods for preparing the compounds of formula I.

EC2002004393A 2000-06-22 2002-12-13 SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH ECSP024393A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
ECSP024393A true ECSP024393A (en) 2003-02-06

Family

ID=22793862

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004393A ECSP024393A (en) 2000-06-22 2002-12-13 SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH

Country Status (42)

Country Link
US (2) US6890924B2 (en)
EP (1) EP1292591B1 (en)
JP (1) JP4044839B2 (en)
KR (1) KR100545537B1 (en)
CN (3) CN1330640C (en)
AP (1) AP2001002192A0 (en)
AR (1) AR032353A1 (en)
AT (1) ATE288431T1 (en)
AU (1) AU2001264159A1 (en)
BG (1) BG107269A (en)
BR (1) BR0111548A (en)
CA (1) CA2413424C (en)
CZ (1) CZ20023951A3 (en)
DE (1) DE60108754T2 (en)
DK (1) DK1292591T3 (en)
DZ (1) DZ3407A1 (en)
EA (1) EA005525B1 (en)
EC (1) ECSP024393A (en)
EE (1) EE200200710A (en)
ES (1) ES2236240T3 (en)
GE (1) GEP20063831B (en)
HR (1) HRP20021005A2 (en)
HU (1) HUP0301120A2 (en)
IL (1) IL152985A0 (en)
IS (1) IS6616A (en)
MA (1) MA26914A1 (en)
MX (1) MXPA02012870A (en)
MY (1) MY127181A (en)
NO (1) NO20026166L (en)
NZ (1) NZ522568A (en)
OA (1) OA12291A (en)
PA (1) PA8520301A1 (en)
PE (1) PE20020257A1 (en)
PL (1) PL359557A1 (en)
PT (1) PT1292591E (en)
SK (1) SK17102002A3 (en)
SV (1) SV2002000504A (en)
TN (1) TNSN01091A1 (en)
UA (1) UA73990C2 (en)
WO (1) WO2001098277A2 (en)
YU (1) YU95102A (en)
ZA (1) ZA200210231B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
PT1117653E (en) * 1998-10-01 2003-06-30 Astrazeneca Ab QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS CYTOSINE MEDIUM-INHIBITORS
CN1330640C (en) * 2000-06-22 2007-08-08 辉瑞产品公司 Substituted bicyclic derivatives for the treatment of abnormal cell growth
ATE475652T1 (en) * 2001-02-21 2010-08-15 Mitsubishi Tanabe Pharma Corp QUINAZOLINE DERIVATIVES
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
AU2002337428A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
EA007412B1 (en) * 2001-12-12 2006-10-27 Пфайзер Продактс Инк. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinaziolin-6-yl}-allyl)-acetamide, method for operating thereof and use in treating cancer
EP1465632A1 (en) * 2001-12-12 2004-10-13 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP4703183B2 (en) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． Receptor kinase modulator and method of use thereof
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
EP1567506A4 (en) 2002-11-20 2007-06-20 Array Biopharma Inc Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
MXPA05006335A (en) * 2002-12-18 2005-08-26 Pfizer Prod Inc 4-anilino quinazoline derivatives for the treatment of abnormal cell growth.
KR20050085835A (en) * 2002-12-19 2005-08-29 화이자 프로덕츠 인코포레이티드 Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
BRPI0409233A (en) * 2003-04-09 2006-03-28 Pfizer Prod Inc processes for the preparation of n - (((((pyridinyloxy) -phenylaminoquinazolinyl) -allyl) acetamide derivatives and related compounds, as well as intermediates of such processes and processes for the preparation of such intermediates)
JP2007501854A (en) * 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク Quinazolines and pyrido [3,4-D] pyrimidines as receptor tyrosine kinase inhibitors
KR101218213B1 (en) * 2003-07-03 2013-01-04 시토비아 인크. 4--4-Arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
CA2529777A1 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
PL1660090T3 (en) * 2003-08-14 2013-04-30 Array Biopharma Inc Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005016347A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
RU2378268C2 (en) 2003-09-16 2010-01-10 Астразенека Аб Quinoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
CA2544863A1 (en) * 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (en) 2004-02-03 2008-12-18 Astrazeneca Ab quinazoline derivatives
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
NZ552091A (en) 2004-07-16 2009-09-25 Pfizer Prod Inc Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
CN101010304A (en) * 2004-09-01 2007-08-01 三菱制药株式会社 Molecular chaperone function regulator
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (en) 2004-12-29 2007-07-04 한미약품 주식회사 Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR100990027B1 (en) 2005-04-26 2010-10-26 화이자 인코포레이티드 P-cadherin antibody
CA2610491A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
PT1933871E (en) 2005-09-07 2013-07-17 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
JP5134548B2 (en) * 2005-11-15 2013-01-30 アレイ バイオファーマ、インコーポレイテッド N4-phenylquinazolin-4-amine derivatives and related compounds as ErbBI type receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
BRPI0711358A2 (en) 2006-05-09 2011-09-27 Pfizer Prod Inc cycloalkylamino acid derivatives and their pharmaceutical compositions
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc Multi-functional small molecules as anti-proliferative agents
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8604044B2 (en) * 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
KR20090090336A (en) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 Fused Heterocyclic Compound
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
JP5336516B2 (en) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Spirocyclic heterocyclic compounds, pharmaceuticals containing the compounds, uses thereof and methods for producing the same
AR070874A1 (en) 2008-03-12 2010-05-12 Takeda Pharmaceutical FUSIONED HETEROCICLIC COMPOUND, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE TREATMENT OF CANCER.
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP2313397B1 (en) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
KR20230008268A (en) 2009-01-16 2023-01-13 엑셀리시스, 인코포레이티드 Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
WO2012052948A1 (en) 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
WO2013042006A1 (en) 2011-09-22 2013-03-28 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
CN102872018B (en) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 Tyrosine kinase irreversible inhibitor and preparation method and applications thereof
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
US20170050958A1 (en) 2014-04-30 2017-02-23 Pfizer Inc. Cycloalkyl-Linked Diheterocycle Derivatives
KR101589632B1 (en) 2014-06-03 2016-02-01 한국과학기술연구원 6-Benzyloxyquinazolin-7-ylurea derivatives with an anticancer activity
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CN107922609B (en) 2015-07-01 2020-04-24 加州理工学院 Delivery system based on cationic mucic acid polymers
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10828305B2 (en) 2016-03-01 2020-11-10 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CA3099776A1 (en) 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents
JP2025509995A (en) * 2022-03-28 2025-04-11 江蘇恒瑞医薬股▲ふん▼有限公司 Nitrogen-containing heterocyclic compounds, their preparation method and medicinal use
WO2025067396A1 (en) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
KR100860295B1 (en) 1998-10-08 2008-09-25 아스트라제네카 아베 Quinazoline derivatives
JP3270834B2 (en) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CN1330640C (en) * 2000-06-22 2007-08-08 辉瑞产品公司 Substituted bicyclic derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
YU95102A (en) 2005-11-28
CZ20023951A3 (en) 2004-01-14
ZA200210231B (en) 2004-02-12
PT1292591E (en) 2005-06-30
SV2002000504A (en) 2002-10-24
SK17102002A3 (en) 2004-04-06
BG107269A (en) 2003-06-30
PL359557A1 (en) 2004-08-23
ES2236240T3 (en) 2005-07-16
EP1292591B1 (en) 2005-02-02
US6890924B2 (en) 2005-05-10
HK1069576A1 (en) 2005-05-27
WO2001098277A2 (en) 2001-12-27
EA200201277A1 (en) 2003-06-26
CN1437594A (en) 2003-08-20
JP2004501139A (en) 2004-01-15
GEP20063831B (en) 2006-05-25
CN1330640C (en) 2007-08-08
NO20026166D0 (en) 2002-12-20
AR032353A1 (en) 2003-11-05
CA2413424A1 (en) 2001-12-27
DZ3407A1 (en) 2001-12-27
DE60108754D1 (en) 2005-03-10
CN101348467A (en) 2009-01-21
UA73990C2 (en) 2005-10-17
HUP0301120A2 (en) 2003-08-28
MA26914A1 (en) 2004-12-20
NZ522568A (en) 2004-12-24
ATE288431T1 (en) 2005-02-15
IL152985A0 (en) 2003-06-24
NO20026166L (en) 2002-12-20
US20050159435A1 (en) 2005-07-21
KR100545537B1 (en) 2006-01-25
DE60108754T2 (en) 2005-06-23
CN1576275A (en) 2005-02-09
HRP20021005A2 (en) 2004-02-29
CA2413424C (en) 2007-10-02
WO2001098277A3 (en) 2002-06-13
BR0111548A (en) 2003-05-06
OA12291A (en) 2004-03-18
US20020169165A1 (en) 2002-11-14
JP4044839B2 (en) 2008-02-06
EE200200710A (en) 2004-06-15
PA8520301A1 (en) 2003-06-30
MXPA02012870A (en) 2003-05-14
US7332493B2 (en) 2008-02-19
EP1292591A2 (en) 2003-03-19
AP2001002192A0 (en) 2002-12-21
EA005525B1 (en) 2005-04-28
TNSN01091A1 (en) 2005-11-10
MY127181A (en) 2006-11-30
KR20030016303A (en) 2003-02-26
DK1292591T3 (en) 2005-05-30
AU2001264159A1 (en) 2002-01-02
IS6616A (en) 2002-11-14
PE20020257A1 (en) 2002-04-08

Similar Documents

Publication Publication Date Title
ECSP024393A (en) SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH
ECSP055633A (en) NEW BENZOIMIDAZOLUTILES DERIVATIVES AS ANTIPROLIFERATIVE ANGENTS
UY28135A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
PA8487601A1 (en) USEFUL SUBSTITUTED BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER
AR046297A1 (en) DPP INHIBITORS - IV METHODS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS ACTIVE AGENTS
CU23132A3 (en) NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
PA8490601A1 (en) QUINOLIN-2-ONA DERIVATIVES SUBSTITUTED WITH HETEROARILO USEFUL AS ANTICANCERIGEN AGENTS.
UY28132A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
DK1697370T3 (en) Azabicyclic heterocyclic compounds as cannabinoid receptor modulators
UY27685A1 (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS, AND PROCEDURES FOR USE
UY28357A1 (en) DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION OF THE SAME AND ITS USES
DOP2002000519A (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
PA8592801A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
UY29134A1 (en) SULFONAMIDS REPLACED BY BENCIMIDAZOL DERIVATIVES, COMPOSITIONS THAT CONTAIN IT, PREPARATION PROCEDURE AND APPLICATIONS
PA8474401A1 (en) 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN
UY26785A1 (en) SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
UY27557A1 (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH.
DOP2003000786A (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH.
UY28131A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
ECSP993260A (en) USEFUL SUBSTITUTE BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER
BRPI0515835A (en) tetraline and indane derivatives and their uses
ECSP993117A (en) DERIVATIVES OF QUINOLIN -2 - ONA USEFUL AS AGENTS AGAINST CANCER
ECSP003347A (en) QUINOLIN DERIVATIVES - 2- ONA SUBSTITUTED WITH HETEROARILO USEFUL AS ANTI-BANERIGINAL AGENTS
CR6833A (en) SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
GT200100120A (en) REPLACED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH